Thrombocytopenia following Pfizer and Moderna <scp>SARS‐CoV</scp>‐2 vaccinationEun‐Ju Lee(NewYork–Presbyterian Hospital), James B. Bussel(NewYork–Presbyterian Hospital)American Journal of HematologyFebruary 19, 202110.1002/ajh.26132Cited by 387SaveCiteExport RISWatch citationsRelated PapersEfficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial|The Lancet|2008|862Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia|Blood Advances|2020|109Inhibition of <scp>FcRn</scp> with rozanolixizumab in adults with immune thrombocytopenia: Two randomised, double‐blind, placebo‐controlled phase 3 studies and their open‐label extension|British Journal of Haematology|2024|13